肿瘤免疫：生物创新【研报】

pengxuleo

$ G: }, ?( ^4 t5 M* d" _& D/ w5 y: x3 ?/ O3 p: x! U, Q- I' y
目录; |4 }  X/ l6 n1 ?$ g7 ?& a# R
免疫治疗引领肿瘤治疗新模式 ...................................................................................................... 4
) n( x0 i' S& |1 a& |7 s抗癌领域新突破 .................................................................................................................. 4
$ k, N  A. X2 R: n600 亿美元市场空间 ............................................................................................................ 4
7 |7 D& X3 r6 _免疫检查点的突破——PD-1 ....................................................................................................... 5
: b% r, ~% V$ mPD-1 单抗——肿瘤免疫治疗的明星 .......................................................................................... 50 z  ?" M  v# ?/ {" O9 k
PD-1 重磅产品频出 ............................................................................................................. 56 c% L9 t) d) s+ A, m
在研PD-1 单抗全面开花 ....................................................................................................... 6
, l" ~5 _" @9 Y/ Q, v6 f, t- XPD-1 临床试验数据——适应人群广泛，效果显著 .......................................................................... 7
" E. y) K& x! w5 t4 EPD-1 以优秀的临床表现快速斩获非小细胞肺癌适应症 .................................................................... 9
- e9 Z3 [1 w( x) V1 y$ _6 ZPD-1 联用——免疫鸡尾酒疗法引爆行业增长点 ............................................................................ 93 c9 f& V$ B8 j6 g' V! |) {9 g0 C
PD-1 市场前景广阔 ........................................................................................................... 10
4 u9 ?& u+ y4 V$ A. ^. G免疫治疗热门靶点——PD-L1 ................................................................................................... 19
- U4 N0 O' D2 yPD-L1 单抗免疫疗法原理 .................................................................................................... 19
+ F6 ?* }# h* V/ b2 SPD-L1 单抗在研情况 .......................................................................................................... 19) f! d- V; ^% n/ _  b, T9 E$ `
PD-L1 联用——多靶点治疗新选择 ......................................................................................... 19
* \$ [. p0 e2 B# ?* sPD-L1 未来市场 ............................................................................................................... 20+ H* w: {8 b+ ^) H# \
免疫治疗另一靶点——CTLA-4 .................................................................................................. 21
; L1 h+ v& m# J4 {. HCTLA-4 单抗免疫疗法原理 ................................................................................................... 21
* @* u9 X1 J- R/ L! yCTLA-4 单抗已上市产品 ..................................................................................................... 21
+ L& r" {4 P8 U+ @9 e% s4 b3 ZCTLA-4 在研产品.............................................................................................................. 22( ]; T3 Q/ T/ P6 e
CTLA-4 的未来，联合用药是出路 .......................................................................................... 23" c9 t( F. M2 Q& M: P' B
相关公司简介 ........................................................................................................................ 24
9 A6 A; t/ ?! E君实生物 ........................................................................................................................ 242 {' O/ X2 P0 s% s  b
恒瑞医药（确信买入评级） .................................................................................................. 25
2 o& K, _+ Z4 A, Q' h百时美施贵宝（BMS） ....................................................................................................... 26- M- K0 z$ c/ l
默克（Merck） ................................................................................................................ 27- s8 i/ Z4 I5 G* X. Y

6 \) T  C; a7 A& {, z/ Z5 n- n4 }
, ?6 a: [! w% C0 X  U9 v* }" E[hide][/hide]

cantonchn

saberche

好好学习一下

chimo100

谢谢

xiaoheilong

感谢分享！

18351507829

本本9705

xx

FreeCell

看看

yinfuhua

学习。

kblb1983

谢谢分享